{"schema_version":"secwatch.filing_event.v1","accession":"0001206774-22-001546","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2022-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.141320+00:00","generated_at":"2026-06-25T01:47:39.773851+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Geron CMO Aleksandra Rizo resigns; Faye Feller named new CMO","bullets":["Dr. Aleksandra Rizo resigns as EVP and CMO, effective July 8, 2022, to join a private discovery-stage biotech.","Rizo will remain as Senior Medical and Regulatory Advisor, assisting with IMerge Phase 3 trial data and potential NDA.","Dr. Faye Feller promoted to EVP and CMO effective July 9; she joined Geron in 2019 from Janssen.","Feller previously served as Study Responsible Physician for imetelstat's IMbark Phase 2 trial at Janssen."],"urls":{"canonical":"https://secwatch.observer/filing/0001206774-22-001546","json":"https://secwatch.observer/filing/0001206774-22-001546.json","markdown":"https://secwatch.observer/filing/0001206774-22-001546.md","text":"https://secwatch.observer/filing/0001206774-22-001546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000120677422001546/0001206774-22-001546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000120677422001546/geron4073661-8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T01:47:39.773851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"340fd2dfde","claim":"Faye Feller was appointed as Executive Vice President and Chief Medical Officer at GERON CORP.","evidence_excerpt":"Effective as of July 9, 2022, Faye Feller, M.D., will assume the duties and responsibilities of Executive Vice President and Chief Medical Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886744/000120677422001546/0001206774-22-001546-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"8031b9deca","claim":"Aleksandra Rizo resigned as Executive Vice President and Chief Medical Officer at GERON CORP.","evidence_excerpt":"On June 9, 2022, Aleksandra Rizo, M.D., Ph.D., notified Geron Corporation (the “Company” or “Geron”) of her decision to resign from her position as Executive Vice President and Chief Medical Officer of the Company, with her last day of employment being July 8, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886744/000120677422001546/0001206774-22-001546-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President and Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}